ABSTRACT
The galectins are a family of evolutionayconserved carbohydrate-binding proteins. They are distributed widely in all living organisms and have been implicated in many essential functions including development, differentiation, cell-cell adhesion, cellmatrix interaction, growth regulation, apoptosis. Several members of the galectin family have also been shown to be involved in cancer progression and metastasis. In the case of galectin-7, several studies have reported alterations in its expression pattern during cancer progression. In a variety of tumors, its expression can range from being completely down-regulated to highly up-regulated. Accordingly, its precise role in this field is still debated. The evidence shows that galectin-7 may promote or inhibit cancer development. In this article, we review the data concerning expression and roles of galectin-7 in cancer and propose a comprehensive view of its contribution during cancer progression.
INTRODUCTION
In recent years, cancer-associated changes in protein glycosylation have generated considerable interest. Accordingly, carbohydrate-binding proteins (lectins) that are present in the extracellular matrix (ECM) and have high affinities for specific oligosaccharide structures expressed on the cell surface have emerged as promising markers for and therapeutic targets in a large number of diseases, including cancer. This is particularly true for members of the galectin family. A role of galectins in cancer invasion and metastasis has been well documented. However, most of the attention has been focused on galectin-1 and galectin-3, and thus we still know very little about how galectin-7 expression affects cancer progression and how distinctive its role is. Although most studies report that galectin-7 is associated with apoptosis, a number of observations suggest that it may paradoxically promote disease progression. Here, we offer an explanation for this paradox and discuss data suggesting that galectin-7 may serve as a novel marker for and a therapeutic target in some forms of cancer.
GALECTIN-7: COMPARISON WITH OTHER MEMBERS OF THE GALECTIN FAMILY.

Galectins
Galectins constitute a family of lectins defined by shared consensus amino acid sequences and affinities for beta-galactose-containing oligosaccharides (1). In humans, galectins are numbered according to the order of their discovery, and the 15 members of the family are normally classified according to their structure and number of carbohydrate recognition domains (CRD) (2,3) . The galectins have either one (Galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15 ) or two (Galectin-4, -6, -8, -9, and -12) CRD linked by a hinge peptide. Typically, CRD are located in the C-terminal end of a protein and consists of a typical β-sandwich fold of approximately 130 amino acid residues that are conserved in all galectins and that include a glycine which stabilizes galectin-carbohydrate interactions (4-7). Analysis of the three-dimensional structure of galectin-7 reveals its homology to galectin-1 and galectin-3, although its overall structure more closely resembles galectin-10, a lysophospholipase expressed primarily in eosinophils, basophils, and some T cells (8, 9). Although early reports suggested that galectin-7 was a monomer (10), further analyses of its crystal structure and its aggregation properties by mass spectrometry indicated that it has the ability to form homodimers (11, 12).
Distinctive expression pattern of galectin-7
Unlike other most commonly studied galectins, galectin-7 exhibits a high degree of tissue specificity; its expression is restricted mostly to stratified epithelial cells of the esophagus, tongue, lip, and epidermis (13, 14). Galectin-7 is found in several types of epithelial cells, including epithelial cells of hair follicles, the esophagus, the oral epithelia, the cornea, Hassall's corpuscles of the thymus, the urinary system, the stratified squamous epithelium of the forestomach, and mammary myoepithelial cells (13, 15-17) (Table 1) . Accordingly, high levels of galectin-7 are found in HaCaT cells, a transformed keratinocyte cell line, and in MDA-MB-468, a human breast cancer cell line. Although aggressive lymphoma cells may express galectin-7 constitutively, cell lines derived from the lymphoid and myeloid lineages, such as Jurkat T lymphoma cells, do not express detectable levels of galectin-7 (18, 19).
Although a number of stimuli have been shown to positively or negatively regulate galectin-7 expression in different cell types (Tables 2 and 3) , the molecular mechanisms regulating the cellular specificity of galectin-7 expression remain poorly characterized. The expression of galectin-7, like that of other members of the galectin family, is partially controlled by epigenetic mechanisms, such as DNA methylation (20-23). This conclusion is largely based on experiments showing that treatment of cell lines with DNA methyltransferase inhibitors, such as 5-aza-2'-deoxycytidine (5-aza-dC), can induce galectin-7 expression in cells that do not normally express the protein, such as Jurkat T lymphoma cells and HCT116 colon cancer cells (18, 24) . Genome profiling experiments comparing several cell lines and primary cells (such as primary dermal fibroblasts) with or without 5-aza-dC treatment have also revealed a possible link between DNA hypomethylation and galectin-7 expression (25-27). A positive correlation between the hypomethylation state of the galectin-7 promoter and constitutive expression of galectin-7 has also been reported (24). Whether DNA hypomethylation favors the binding of specific transcription factors to the galectin-7 promoter is currently unclear. In fact, the identity of the transcription factors that regulate galectin-7 expression remains largely unknown. Results from gene profiling experiments indicate, however, that a number of transcription factors may be involved in inducing or repressing galectin-7 expression. The first transcription factor shown to regulate galectin-7, at least in colorectal cancer cells, was p53 (28). A study from the group of Bert Vogelstein revealed that galectin-7 mRNA was one of the 14 transcripts (or "PIG's", for p53-induced genes) out of Computational analysis of the human and mouse galectin-7 promoters reveals the presence of several conserved consensus sites, including those for NF-κB subunits and GATA-3. These transcription factors are among the prime candidates for regulation of galectin-7 expression. We have identified an inverse relationship between GATA-3 and galectin-7 expressions in mammary tumor cells (15). A relationship between NF-κB, which is a major antiapoptotic factor (31), and galectin-7 was also reported recently, in a series of gene pathway profiling experiments aimed at identifying networks of molecular interactions of genes expressed in highly metastatic variants of 4T1-derived breast tumors (32). Whether these transcription factors play a role in galectin-7 expression in specific cell types and/or cancer remains, however, to be established.
Cellular localization of galectin-7
Historically, the cellular localization of galectins has been a subject of intense scrutiny, given the multiple roles of these proteins. A general assumption is that galectins exist in extracellular and intracellular compartments. Although they do not harbor a signal sequence, the members of galectin family can be secreted through a non-classical secretory pathway, sometimes in galectin-rich vesicles or cell-derived exosomes following exocytic fusion with plasma membranes (33-35). Consequently, they have often been found in the sera of normal subjects and cancer patients. For example, normal individuals have detectable levels of galectin-3 in their serum, while patients with metastatic disease have significantly higher levels of galectin-3 compared to normal individuals or patients with localized tumors (36-38). ELISAs have also been used to demonstrate secretion of galectin-1 into the culture medium by a number of different cell types, including specific subsets of B and T cells, endothelial cells, and multipotent mesenchymal stromal cells (39-42). Accordingly, recombinant galectins have been extensively used to study various carbohydratedependent extracellular functions in various in vitro model systems. These studies have shown that secreted forms of galectins bind and crosslink widely expressed cell surface receptors harboring the appropriate oligosaccharides. Such oligomeric interactions create lattices or microdomains that regulate glycoprotein mobility in the plane of the membrane (43). For example, the binding of galectin-3, -8, or -9 to β1,6GlcNAc-branched N-glycans on the extracellular surface of the EGFR induces the formation of a transient dynamic lattice that opposes receptor loss through endocytosis, thus maintaining its sensitivity to ligand binding (44). To our knowledge, however, there is no indication that galectin-7 participates in the formation of such structures. This may be due to the fact that galectin-7 is preferentially found in intracellular compartments. Although cell binding studies using recombinant galectin-7 has revealed that galectin-7 binds to the cell surface in a carbohydrate-dependent manner (12) and can stimulate MMP-9 expression (19), most studies have reported that galectin-7 expression is restricted to the cytoplasm and the nucleus (Table 1) . Our group and others have also failed to detect significant levels of galectin-7 in sera from both healthy individuals and cancer patients (45). Analyses of supernatants from HaCaT or mammary epithelial cells lines using either ELISAs or western blots have also failed to provide evidence for a secreted form of galectin-7 in these cells, even when galectin-7 is expressed at high levels into the cytoplasm following transfection with an expression vector encoding human or mouse galectin-7 (15). Similarly, no immunoreactivity could be detected in COS-1 or HeLa cells transfected with a cDNA encoding galectin-7 (10, 46). Galectin-7 seems to be preferentially found in intracellular compartments, possibly interacting with the cytoskeleton (10). Although the reason why galectin-7 (in contrast to other galectins) cannot be detected in the serum is currently unclear, we believe that investigation of the role of galectin-7 in normal and pathological processes should focus on intracellular compartments rather than extracellular spaces.
GALECTIN-7 IN CANCER
The pro-apoptotic function of galectin-7: a logical role in suppressing tumor growth
Members of the galectin family are well known for their ability to promote apoptosis, and a large number of reviews have documented the role of galectins in apoptosis. Based on the idea that galectin-7 shares functions with its family, most of the investigations concerning galectin-7 have thus focused on its implication in apoptosis. This link between apoptosis and galectin-7 was initially proposed in the study linking induction of its expression to that of p53 in colon cancer cells (28). Given its preferential distribution in epithelial cells, the ability of galectin-7 to modulate apoptosis was believed to play an important role in epidermal homeostasis, since apoptosis is an essential mechanism for maintaining epidermal integrity (13, 47). This role was further supported by a study by Bernerd et al., (48) who reported that both mRNA and protein levels of galectin-7 were increased in cultured keratinocytes after UVB radiation. They also found that sunburned/apoptotic keratinocytes expressed higher levels of galectin-7 than other keratinocytes and that galectin-7 overexpression induces a significant increase in terminal deoxynucleotidyltransferasemediated UTP end labeling (TUNEL)-positive keratinocytes. It is thus not surprising that galectin-7 plays a role in epithelial cell migration and in the re-epithelization of corneal and/or epidermal wounds (49-51). Such a role for galectin-7 in the homeostatic control of epithelia is supported by recent studies using galectin-7-deficient mice. Using these mice, Gendronneau et al. (52) showed that galectin-7 helps to maintain epidermal homeostasis in response to UVB irradiation and wounding. Ectopic expression of galectin-7 in DLD-1 cells also made them more sensitive to a number of different apoptotic stimuli (53). Moreover, DLD-1 transfectants overexpressing galectin-7 grew significantly slower than control transfectants, most notably following injection into severe combined immunodeficient (SCID) mice. This antiproliferative effect of galectin-7 does not seem to be restricted to colorectal cancer cells, because galectin-7 also renders HeLa cells more sensitive to apoptotic stimuli (46). These studies also showed that galectin-7's pro-apoptotic function was most likely performed by its intracellular form, because it was found to localize in the nuclei and cytoplasm in various cell types, including HeLa and HaCaT cells. Galectin-7 is thus distinct from other members of the galectin family with regards to the mechanisms by which they modulate apoptosis. Galectin-1 and galectin-9, for example, induce tumor cell apoptosis when added to the extracellular space, whereas galectin-7, galectin-3, and galectin-12 seem to promote apoptosis through intracellular mechanisms (54).
This ability of galectin-7 to inhibit cell proliferation may not always be linked to its pro-apoptotic function. Galectin-7-mediated inhibition of proliferation in neuroblastoma cells, for instance, can be achieved without any signs of apoptosis (12). In this case, the anti-proliferative effect seem to be mediated through extracellular binding of recombinant galectin-7 to specific cell surface receptors and could be blocked by addition of extracellular galectin-3, supporting the idea that galectin-7 and galectin-3 may have distinct functions. The specific identity of these surface receptors involved remains unclear, however. Because recombinant galectin-7 can bind non-reducing terminal LacNac residues on cell surface receptors as well as internal LacNac oligosaccharide residues (55), the number of receptors that could potentially bind extracellular galectin-7 is relatively large.
Unexpected roles of galectin-7 in cancer
At first glance, it seems that, given its link with apoptosis and its anti-proliferative effects, galectin-7 should have a negative role in tumor progression. Observations made in several experimental model systems suggest, however, that galectin-7 expression is increased in tumors and may thus favor tumor progression (Table 4 ). The first hint that galectin-7 may be associated with tumor progression was found in a study reported by Lu et al. (56) .
Using an experimental rat model of chemically induced mammary carcinoma, Lu and colleagues found that galectin-7 was overexpressed in mammary tumors as compared to normal mammary tissues. Our work in lymphoma and breast cancer also support the possibility that galectin-7 may promote tumorigenesis. In lymphoma, we have shown that galectin-7 expression was induced in aggressive T lymphoma cells generated upon in vivo passages on non-aggressive lymphoma cells in syngenic immunocompetent mice (18). Such a strategy for generating highly metastatic tumor cell lines has been successfully used in the past to identify genes that are involved in tumor progression (for examples, see (57) and (58)). Similar increases in the level of galectin-7 were found in a significant proportion of mature human B-cell lymphoid neoplasms but not in normal B lymphocytes (59) . This abnormal expression of galectin-7 is believed to favor dissemination of lymphoma cells; mice injected with T lymphoma transfectants expressing high levels of galectin-7 developed large metastatic tumors in the liver and kidneys with massive infiltration of tumor cells in the parenchyma as compared to mice injected with control lymphoma cells (19). In contrast, only a few scattered tumor foci with limited infiltration were observed when galectin-7 expression was suppressed in highly aggressive lymphoma cells (59) . The ability of galectin-7 to induce expression of MMP-9, a gene known to confer clinical aggressiveness upon lymphoma cells, may in part explain this capacity of galectin-7 to increase metastasis. This hypothesis is supported by a number of experiments in human cancer (Table 5) . Additionally, galectin-7 may confer resistance to apoptosis (15). Indeed, galectins do not always induce or promote apoptosis. For example, it is No data (131) well-known that galectin-3 is associated with resistance to apoptosis in a large number of cell types and diseases, including cancer, and in response to various pro-apoptotic stimuli (reviewed in (60)). Such mechanisms may also explain the ability of galectin-7 to promote metastasis of breast cancer cells to the bone and lung. Using wellcharacterized breast cancer models, we have found that de novo expression of galectin-7 in 4T1 and 66c14 mammary epithelial cells increases their metastatic potential when injected into syngenic Balb/c mice (15). Again, as we observed in lymphoma, aggressive variants of 4T1 mammary cells that metastasize to the bone express higher levels of galectin-7 than their non-aggressive counterparts.
Galectin-7: a marker for mammary myoepithelial cells and aggressive breast cancer?
In humans, invasive breast carcinomas can be categorized into the following distinct subtypes: luminal A, luminal B, HER2-positive, and basal-like (61)(62). While luminal A and luminal B breast cancer subtypes express the estrogen receptor (ER) and/or progesterone receptor (PR), HER2-positive and basal-like subtypes are hormone receptor negative and have a more aggressive phenotype and a worse prognosis than luminal-type breast carcinomas (61) (62) (63) (64) . Immunohistochemical experiments using antigalectin-7 specific antibodies on tissue microarrays (TMAs) constructed from samples obtained from normal breast tissues and breast carcinomas revealed that galectin-7 is exclusively expressed in HER2-positive and ER/PRnegative basal-like breast cancer (15). Not surprisingly, many human basal-like breast cancer cells, such as MDA-MB-468, express galectin-7 constitutively (Y. St-Pierre, unpublished). In contrast, most human or mouse breast cancer cell lines with luminal characteristics do not express galectin-7. Interestingly, we also have found that galectin-7 was specifically expressed in mammary myoepithelial (or basal) cells but not in mammary luminal epithelial cells (15). Overall, it is clear that this expression pattern is different from that other galectins, such as galectin-3, which is specifically expressed in normal luminal epithelial cells (65) . Moreover, in contrast to galectin-7, galectin-3 is downregulated during breast cancer progression (66) . Thus, if we consider galectin-7 a specific marker of myoepithelial cells (as opposed to luminal cells), this pattern of expression would be consistent with the hypothesis that basal-like breast cancer originates from myoepithelial cells (67) . This hypothesis remains controversial, however, because several other markers that are specifically expressed in myoepithelial cells are not expressed in basallike breast cancers (68) . How the luminal and myoepithelial lineages are maintained is currently unclear, although recent work indicates that expression of GATA-3 is essential for luminal differentiation (69) . Interestingly, we found that overexpression of galectin-7 is related to absence of GATA-3 (15). These observations, which concerned the protein level, are corroborated by results obtained at the mRNA level in several microarray analyses aimed at defining specific markers for myoepithelial cells or basal-like breast cancers. Microarray studies on normal breast luminal and myoepithelial cells from Jones et al. identified galectin-7 as a myoepithelial-specific gene (70) .
In fact, galectin-7 ranked first on the list among the 42 most predictive genes that distinguish luminal from myoepithelial cells. A close examination of the genomic profiling data reported by Perou et al., (63) , who provided a molecular portrait of 65 surgical specimens of human breast tumors from 42 individuals, reveals that galectin-7 transcripts are highly expressed in cell lines with a basallike phenotype. Whether the association between galectin-7 and aggressive breast cancer and the ability of galectin-7 to promote metastasis are linked to MMP-9, as is the case in lymphoma, remains to be tested. Interestingly, in breast cancer, suppression of MMP-9 expression using RNAi technology resulted in complete regression of orthotopic breast tumors in nude mice (71) . Similarly, ablation of MMP-9 expression by RNAi inhibits tumor invasion in human breast cancer cells (72). Such a possibility is reminiscent of another major role played by galectins -that of promoting cancer cell migration and leading to the formation of metastases. Levels of galectin-1, -3, and 8, for instance, have been shown to modulate cell-cell and cell-ECM contacts during migration to promote integrinmediated cell adhesion and migration of tumor cells and leukocytes at different stages of metastasis (54, 73-75).
OTHER FUNCTIONS FOR GALECTIN-7
Given its specific cellular distribution, it is logical to believe that while galectin-7 shares some functional characteristics with other members of the galectin family, it may fulfill different specific functions in specific cell types (notably in epithelial cells, where it is highly expressed). For instance, galectin-7 is believed to counteract TGFβ-mediated effects (76) . During their investigations aimed at elucidating how hepatocyte growth factor (HGF) antagonizes TGFβ in hepatocytes, Inagaki and colleagues (76) showed that galectin-7 physically interacts with activated forms of Smad2/3, modulating their nuclear export. In the absence of HGF, Smad2 and 3 are responsible for the induction of COL1A2 following TGFβ stimulation. Such a role for galectin-7 may not be entirely specific; at least one another member of the galectin family, galectin-1, has been shown to interfere with the TGFβ pathway, possibly by preventing Smad2/3 from binding to its specific binding site on the COL1A2 promoter (77) . Physical interaction between galectin-1 and Smad proteins in the nucleus has not, however, been confirmed. On the other hand, the ability of galectin-7 to interfere with the TGFβ/Smad pathway clearly differs from that of galectin-3, which is elevated in human liver fibrosis and which has been shown to be essential for TGFβ−mediated myofibroblast activation and matrix production (78) . Thus, while induction of galectin-7 (or galectin-1) expression may prevent hepatic injury, galectin-3 expression must be repressed in order to develop a galectin-based therapeutic approach to the prevention and treatment of liver fibrosis. In cancer, however, this ability of galectin-7 to interfere with Smad2/3-mediated functions may explain, at least in part, its ability to promote cancer progression, because inhibition of Smad3 in mice promotes tumorigenesis (79) Figure 1 . Dual roles of galectin-7 in suppressing and promoting tumor growth. In cancer, the effect of galectin-7 response is highly contextual. De novo expression of galectin-7 by p53 is associated with apoptosis, thereby inhibiting tumor growth. Alternatively, galectin-7 may modulate cancer progression by interfering with Smad3. Smad3 is a key regulatory protein in the TGFb signaling pathway, which is known to exert both tumor-suppressive and tumor promoting effects. Paradoxically, galectin-7 may also induces expression of genes that promote cancer progression, including MMP-9, thereby modulating microenvironment modification that cancer cells may exploit to their advantage. In this case, galectin-7 expression could be induced by NF-κB, a gene known to be expressed in highly aggressive tumor cells and a positive regulator of MMP-9. Such link between NF-κB and galectin-7 in cancer progression has been suggested by recent gene pathway profiling of a murine breast cancer model. Consequently, therapeutic applications that target galectin-7 needs to be refined by minimizing its protumor functions.
CONCLUDING REMARKS
In addition to sharing several structural features with other members of the galectin family, galectin-7 shares several common functional characteristics. For example, like other members of the galectin family, galectin-7 is characterized by the following: 1) it is found in both the cytoplasm and the nucleus of several cell types; 2) its expression is regulated by DNA methylation, 3) it can positively and negatively modulate apoptosis; and 4) it can favor or suppress cancer cell growth. However, beyond these commonly shared properties, there are an increasing number of indications that galectin-7 may have unique properties, most notably regarding its cellular distribution in specific tissues and its apparent preference for intracellular compartments. If galectin-7 expression is indeed restricted to the cytoplasm and the nucleus, its biological functions may be different from what we originally thought. Although glycosylated proteins are present intracellularly, functional roles by galectin-7 that are independent of its CRD should also be investigated, especially after recent reports on the associations between galectin-7 and specific transcription factors. It is likely that galectin-7 may, in turn, induce the expression of genes essential for tumor invasion and resistance to apoptosis, given its role in inducing MMP genes and its physical interactions with transcription factors (Figure .1) . Future structure-function studies with mutated forms of galectin-7 will help clarify this issue. At the same time, a better characterization of the molecular mechanisms regulating its expression in normal and cancer cells is needed to better understand how galectin-7, originally identified as a p53-induced gene, is highly expressed in some cancer cells, promoting their survival, while promoting cell death in other cell types.
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